文献速递腹部MR

钆塞酸增强MRI鉴别肝脏硬化性血管瘤与恶性肿瘤

Gadoxetic acid-enhanced MRI for differentiating hepatic sclerosing hemangioma from malignant tumor.
PubMed 文献 · Eur J Radiol · 2020-12-13

回顾性病例对照研究纳入18例肝脏硬化性血管瘤与54例常见肝脏恶性肿瘤(肝细胞癌、转移性腺癌、胆管癌),分析钆塞酸增强MRI影像特征。多因素分析显示不规则边缘、移行期向心性或内部结节状强化、无弥散受限为独立预测特征;满足至少两项特征时诊断硬化性血管瘤的敏感度88.9%、特异度96.3%、准确率94.4%。

要点

  • 移行期出现向心性或内部结节状强化是鉴别硬化性血管瘤与恶性肿瘤的关键征象。
  • 无弥散受限对诊断硬化性血管瘤的OR为39.20,是三项特征中效应量最大者。
  • 满足至少两项显著影像特征时,诊断硬化性血管瘤的敏感度88.9%、特异度96.3%、准确率94.4%。

核心结论

  • 联合两项或以上显著影像特征(不规则边缘、移行期向心性或内部结节状强化、无弥散受限)可有效鉴别肝脏硬化性血管瘤与恶性肿瘤。

研究设计与样本

  • 回顾性病例对照研究,纳入18例硬化性血管瘤和54例常见肝脏恶性肿瘤(肝细胞癌、转移性腺癌、胆管癌)。
  • 所有患者于2008年1月至2019年6月接受钆塞酸增强肝脏MRI检查。
  • 分析信号强度、肿瘤边缘、强化方式及有无弥散受限等影像特征,采用多因素logistic回归筛选预测硬化性血管瘤的显著特征。

关键影像表现/征象

  • 不规则边缘:OR 10.12(95%CI 1.27-80.94,p=0.029)。
  • 移行期向心性或内部结节状强化:OR 13.58(95%CI 1.48-124.82,p=0.021)。
  • 无弥散受限:OR 39.20(95%CI 4.82-318.49,p=0.001)。

诊断标准与关键数值

  • 满足至少两项显著影像特征(不规则边缘、移行期向心性或内部结节状强化、无弥散受限)诊断硬化性血管瘤:敏感度88.9%、特异度96.3%、准确率94.4%。

临床应用与阅片要点

  • 阅片时关注移行期是否出现向心性或内部结节状强化,并结合边缘形态及弥散受限情况综合判断。
  • 满足至少两项显著影像特征时,可提示硬化性血管瘤以减少与恶性肿瘤的混淆。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: To investigate the imaging features of gadoxetic acid-enhanced magnetic resonance imaging (MRI) to differentiate hepatic sclerosing hemangioma from malignant tumors.

METHODS: This retrospective case-control study included 18 patients with sclerosing hemangioma and 54 patients with common hepatic malignant tumor, including hepatocellular carcinoma, metastatic adenocarcinoma, and cholangiocarcinoma, who were examined using gadoxetic acid-enhanced liver MRI from January 2008 to June 2019. Imaging features including signal intensity, tumor margins, enhancement pattern, and presence or absence of diffusion restriction were analyzed. Significant MRI features for predicting sclerosing hemangioma were identified using multivariable logistic regression analysis. Diagnostic performances of each imaging feature and combinations of significant imaging features were summarized.

RESULTS: In the multivariable analysis, irregular margins (odds ratio [OR], 10.12; 95 % confidence interval [CI], 1.27-80.94; p = 0.029), centripetal or internal nodular enhancement in the transitional phase (OR, 13.58; 95 % CI, 1.48-124.82; p = 0.021), and absence of diffusion restriction (OR, 39.20; 95 % CI, 4.82-318.49; p = 0.001) were significant imaging features for the diagnosis of sclerosing hemangioma. Presence of at least two significant imaging features had a sensitivity, specificity, and accuracy of 88.9 %, 96.3 %, and 94.4 %, respectively, for diagnosing sclerosing hemangioma.

CONCLUSION: Combinations of two or more of the significant imaging features (irregular margins, centripetal or internal nodular enhancement in the transitional phase, and absence of diffusion restriction) were effective for differentiating hepatic sclerosing hemangioma from malignant tumors using gadoxetic acid-enhanced MRI.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Kim YY, Kang TW, Cha DI, et al. Gadoxetic acid-enhanced MRI for differentiating hepatic sclerosing hemangioma from malignant tumor. Eur J Radiol. 2020. PMID: 33352374. doi:10.1016/j.ejrad.2020.109474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。